Indian Pharmas In Trend To Focus On Targeted Drugs
This article was originally published in PharmAsia News
Indian pharmaceutical companies are joining what appears to be a global trend of pharmas to shift their emphases to specialized or targeted drugs rather than relying on blockbusters. Dr. Reddy's Laboratories, Wockhardt and Lupin Pharmaceuticals are, as are several multinational drug makers, increasingly focused on cancer molecules, monoclonal antibodies and vaccines. Part of the change has come about because of moves by generics makers into supplying medicines used in primary care. (Click here for more
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.